Primary central nervous system lymphoma: Inter-compartmental progression.

Content Provider	Europe PMC
Author	Raval, Vishal Binkley, Elaine Aronow, Mary E. Valenzuela, Juan Peereboom, David M. Wei, Wei Srivastava, Sunil Davanzo, Jaqueline Boldt, Herbert Culver McGarrey, Mark P. Papaliodis, George N. Sobrin, Lucia Kim, Ivana K. Vavvas, Dimitrios G. Eliott, Dean Nayak, Lakshmi Dodds, Emilio Marco del Pont, Francisco Singh, Arun D.
Abstract	AbstractThere is limited understanding of the inter‐compartmental progression and treatment outcomes of primary central nervous system lymphoma (PCNSL). In this multicenter retrospective cohort study on 234 patients with PCNSL (median age: 62.5 years [18–92]; median follow‐up 35 months [0.1–237.0]) from 2000 till 2018 were divided into group 1 (ocular, 44 patients): 1A and 1B without and with CNS progression and group 2 (CNS, 190 patients): 2A and 2B without and with ocular progression, respectively. In group 1 (44 patients), 33 patients received local treatment, and 11 patients received systemic treatment. In group 2 (15 patients), six patients received combination treatment, while seven patients received only systemic treatment. A complete response was observed in 19 (43%) and 91 (48%) patients in groups 1 and 2, respectively. The 2‐year progression‐free survival (PFS) was 35% (95% CI: 0.23, 0.54) and 56% (95% CI: 0.49, 0.63) for groups 1 and 2, respectively (p < 0.0001). Age < 60 years was significantly associated with longer PFS (median PFS 48 vs. 24 months, p = 0.01). The overall survival (OS) at 2‐year was similar among groups 1 and 2 (83% and 67%), respectively (p = 0.06). Thus, Initial compartment of involvement does not influence local response rate or OS.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9175875&blobtype=pdf
Page Count	9
Journal	EJHaem
Volume Number	3
DOI	10.1002/jha2.303
PubMed Central reference number	PMC9175875
Issue Number	2
PubMed reference number	35846050
e-ISSN	26886146
Language	English
Publisher	John Wiley and Sons Inc.
Publisher Date	2022-01-20
Publisher Place	Hoboken
Access Restriction	Open
Rights License	This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Subject Keyword	inter‐compartment primary central nervous system lymphoma primary central nervous system lymphoma‐ocular variant primary vitreoretinal lymphoma progression treatment
Content Type	Text
Resource Type	Article
Subject	Hematology